April Bio

About April Bio

AprilBio is a South Korean biopharmaceutical company developing long-acting biologic and antibody drugs for autoimmune, inflammatory and oncologic diseases. Founded in 2013 by immunologist Sang-Hoon Cha, a professor at Kangwon National University, the company is headquartered in Chuncheon, Gangwon-do, with its R&D center in Seoul, and listed on the KOSDAQ market in July 2022 (KRX: 397030).

The company's core platform is SAFA (anti-Serum Albumin Fab Associated), which uses human Fab antibody fragments that bind serum albumin to extend the half-life of therapeutic proteins, enabling less frequent dosing while improving efficacy and tolerability. Its pipeline includes APB-A1 (an anti-CD40L candidate out-licensed to Lundbeck as Lu AG22515, in Phase 1b development), APB-R3 (an IL-18-targeted long-acting fusion protein partnered with Evommune, which reported positive Phase 2a data in atopic dermatitis in 2026), APB-R5 (out-licensed to Yuhan for co-development), and a further set of autoimmune and oncology candidates built on the SAFA and next-generation REMAP platforms.

AprilBio licenses its candidates and platform technologies to global pharmaceutical partners and is expanding into RNA therapeutics, developing dual-target siRNA drugs and antibody-oligonucleotide conjugates (AOCs) with partner Curigin. In 2026, TKG Taekwang and IMM Investment became the company's largest shareholders through a strategic investment, backing its next phase of R&D and global partnering.